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Abstract 
Epidemiologically prevailing antiphospholipid syndrome (APS) is common among the younger population. APS is 
characterized by recurrent arterial and/or venous thrombosis and miscarriage. Although common among the youth; 
it has gained little or no consideration in its diagnosis in the Ethiopian clinical setup. We identified a woman with 
a movement disorder called chorea and recurrent pregnancy loss (abortions). She stayed eight years to be 
diagnosed with APS. As a devastating disease commonly seen in young patients with stroke, deep vein thrombosis 
and abortion, physician vigilance to detect APS is invaluable. [Ethiop. J. Health Dev. 2018;32(2):123-125] 
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Introduction 
Antiphospholipid syndrome (APS) is a disease first 
described 34 years back. This is known to cause mainly 
clotting disorder and miscarriage (1). 
 
APS is the commonest cause of acquired 
thrombophilia, which can affect any organ in the body 
(lung, liver, kidneys heart, skin, brain and others).It is 
an auto-immune disorder characterized by venous 
and/or arterial thrombosis, recurrent abortions in the 
presence of antiphospholipid antibodies (aPL) i.e. 
Lupus anticoagulant (LA), Anticardiolipinanti bodies 
(aCL), on two or more occasion at a minimum of 
12weeks interval (2).Though its exact prevalence is 
unknown it is estimated to affect 1-4% of the 
population (3), with an estimated prevalence of 40-50 
per 100,000 people (4).It has no specific geographic 
selection in the world and affects all races. Women are 
affected five times more than men, and common 
among those in the age group 30-40 years. Though it 
doesn’t have a cure, if diagnosed early, it can be treated 
successfully. 
 
Current estimates show that APS is responsible for one 
in every six cases of DVT, Pulmonary embolism, 
stroke and myocardial infarction among people under 
the age of 50 years (5).In a population based study a 
PLs were positive in 13% of stroke patients, 11% of 
myocardial infarction,9.5% of DVT and 6% of 
pregnancy morbidity(4).As a disease with multiple 
organ involvement, it can present itself to a diverse 
group of medical specialties- gangrene to the surgeon, 
stroke and chorea as in our patient to the neurologist, 
recurrent fetal loss to the gynecologist and differently 
to others (1). 
 
Despite its critical impact, APS is under diagnosed and 
misdiagnosed in many parts of the world (6).To the 
best of our knowledge and observation much remains 
unknown about APS in Ethiopia, and its diagnosis is 
made rarely even in tertiary referral centers. We 
assume this is partly due to preferential lack of 
awareness about it and partly due to lack of the lab 
tests locally, which necessitates samples to be sent 
abroad and are expensive. 
 
APS is known to affect the central nervous system and 
ischemic stroke via cerebral arterial thrombosis is the 
commonest neurologic manifestation. Movement 
disorders occur rarely in APS and chorea is the 
commonest, while less common ones are 
hemibalismus, Parkinsonism, hemidystonia. The 
etiology of movement disorders is not well understood 
but it is hypothesized that a direct neurotoxic effect of 
a PL or autoimmune injury to the basal ganglia are the 
possible causes. 
 
Patient History: A 32-year- old married women was 
presented at the neurologic follow up clinic at Tikur 
Anbessa Specialized Hospital (TASH) exhibiting 
irregular, involuntary movement involving her head, 
arm and legs since nine years. This symptom started all 
over the body (hands, legs and head) and was milder in 
severity. On additional history she had pregnancy loss 
four times with no known reasons given or 
interventions done, despite having multiple physician 
visits over eight years .The pregnancy loses in the first 
to fourth pregnancy occurred at 9,3,4 and 6 months of 
gestation respectively. By the time she visited TASH 
she had two still births and two miscarriages. She had 
no family history of abnormal body movement and no 
history of recurrent sore throat or chest discomfort. 
Generally she was healthy looking, having records of 
systolic and diastolic hypertension, with no fever. Mini 
Mental Status examination was normal (30/30). Recent 
laboratory tests of CBC, lipid profile, VDRL all were 
normal. On urinalysis initially she had had proteinuria 
(+1) and hematuria (+3), with a creatinine of 1.1 and 
urea 31, which all subsequently either cleared or 
returned to the normal reference range. On Cardiac 
evaluation had holosystolic murmur at apex and 
transthoracic echocardiography showed moderate 
mitral regurgitation, Anti Nuclear Antibody ANA was 
positive, but double stranded DNA (Ds DNA) was 
negative. 
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Brain MRI showed left basal ganglia and peri-
ventricular infarction and mild cerebral atrophy. With 
it a diagnosis of ischemic stroke was made [figure 1]. 
Serum Lupus Anticoagulant LA and Anticardiolipin 
Antibody (aCL) were positive with high titers in two 
serial tests done 12 weeks apart fulfilling the Sydney 
criteria for definite APS(7). Finally after eight long 
years, with a diagnosis of chorea plus recurrent 
pregnancy loss and ischemic stroke secondary to 
primary APS; She was put on clonazepam for the 
Chorea and showed significant improvement and 
needed no additional medication, also she is on 
warfarin for the past nine months and fairly well off 
with no new complaint and no report of pregnancy 
happening so far. 
 
 
Figure 1:  
Brain MRI: T1, T2 and FLAIR (a,b and c respectively) images with left basal ganglia and peri-ventricular Hyper 
intense lesions on T2WI and FLAIR study, Hypointense in T1WI which shows no mass effect suggestive of 
infarction, Mild widening of the cerebral sulci is evident suggestive of mild cerebral atrophy. 
 
Discussion: From this particular case it is clear that 
diagnosis could get delayed for so long resulting in 
needless personal suffering and family tragedy. 
 
APS also can present with multiple neurologic 
symptoms of which ischemic stroke is the commonest 
and rarely with chorea (1.3%) (8).  
 
The patient doesn’t have a history suggestive of 
rheumatic fever, like recurrent sore throat, skin rash of 
rheumatic fever or arthralgia though she had 
echocardiographic abnormalities; in light of her 
fulfilling the criteria for APS the diagnosis of 
Sydenham’s chorea was not considered and APS 
associated chorea was entertained. Of Huntington’s 
disease in this patient, other than the chorea she doesn’t 
have the cognitive deficit of it and as an autosomal 
dominant disorder she doesn’t have similar family 
history. When we see chorea gravidarum that occurs 
during pregnancy and associated with eclampsia and 
use of OCP and tend to have seizure (which our patient 
doesn’t have). With the above mentioned reasons we 
considered her to have Chorea associated with APS.  
 
Conclusion:  
APS is a fairly prevalent condition, especially among, 
young patients with DVT, myocardial infarction and 
stroke. Also it is associated with recurrent pregnancy 
loss or abortion. Every physician and health facility 
dealing with clots, gangrene, stroke, myocardial 
infarction and recurrent abortions is expected to be 
vigilant and have a high index of suspicion of APS, 
which is a fatal syndrome in order to avert potential 
consequences. 
 
In addition, awareness at service provider’s level, 
improving diagnostic capacities by trained 
professionals, equipment and supplies, subsidization of 
costs would improve early diagnosis and prevention of 
fatal consequences of APS. Failure to do so however 
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